» Articles » PMID: 36815036

Structure-activity Relationship of Pyrazol-4-yl-pyridine Derivatives and Identification of a Radiofluorinated Probe for Imaging the Muscarinic Acetylcholine Receptor M

Abstract

There is an accumulating body of evidence implicating the muscarinic acetylcholine receptor 4 (M) in schizophrenia and dementia with Lewy bodies, however, a clinically validated M positron emission tomography (PET) radioligand is currently lacking. As such, the aim of this study was to develop a suitable M PET ligand that allows the non-invasive visualization of M in the brain. Structure-activity relationship studies of pyrazol-4-yl-pyridine derivates led to the discovery of target compound a subtype-selective positive allosteric modulator (PAM). The radiofluorinated analogue, [F], was synthesized in 28 ± 10% radiochemical yield, >37 GBq/μmol and an excellent radiochemical purity >99%. Initial autoradiograms on rodent brain sections were performed in the absence of carbachol and showed moderate specificity as well as a low selectivity of [F] for the M-rich striatum. However, in the presence of carbachol, a significant increase in tracer binding was observed in the rat striatum, which was reduced by >60% under blocking conditions, thus indicating that orthosteric ligand interaction is required for efficient binding of [F] to the allosteric site. Remarkably, however, the presence of carbachol was not required for high specific binding in the non-human primate (NHP) and human striatum, and did not further improve the specificity and selectivity of [F] in higher species. These results pointed towards significant species-differences and paved the way for a preliminary PET study in NHP, where peak brain uptake of [F] was found in the putamen and temporal cortex. In conclusion, we report on the identification and preclinical development of the first radiofluorinated M PET radioligand with promising attributes. The availability of a clinically validated M PET radioligand harbors potential to facilitate drug development and provide a useful diagnostic tool for non-invasive imaging.

Citing Articles

Development of a Selective and High Affinity Radioligand, [H]VU6013720, for the M Muscarinic Receptor.

Qi A, Kling H, Billard N, Rodriguez A, Peng L, Dickerson J Mol Pharmacol. 2023; 104(5):195-202.

PMID: 37595966 PMC: 10586508. DOI: 10.1124/molpharm.122.000643.


Imaging Cholinergic Receptors in the Brain by Positron Emission Tomography.

Zhang J, Fu H, Lin R, Zhou J, Haider A, Fang W J Med Chem. 2023; 66(16):10889-10916.

PMID: 37583063 PMC: 10461233. DOI: 10.1021/acs.jmedchem.3c00573.


Design, synthesis and evaluation of novel 2-phenyl-3-(1H-pyrazol-4-yl)pyridine positive allosteric modulators for the M mAChR.

Jorg M, van der Westhuizen E, Lu Y, Choy K, Shackleford D, Khajehali E Eur J Med Chem. 2023; 258:115588.

PMID: 37423123 PMC: 7616163. DOI: 10.1016/j.ejmech.2023.115588.


Recessive CHRM5 variant as a potential cause of neurogenic bladder.

Schneider S, Schierbaum L, Burger W, Seltzsam S, Wang C, Zheng B Am J Med Genet A. 2023; 191(8):2083-2091.

PMID: 37213061 PMC: 10527291. DOI: 10.1002/ajmg.a.63241.

References
1.
Shannon H, Bymaster F, Calligaro D, Greenwood B, Mitch C, Sawyer B . Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. J Pharmacol Exp Ther. 1994; 269(1):271-81. View

2.
Bubser M, Bridges T, Dencker D, Gould R, Grannan M, Noetzel M . Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. ACS Chem Neurosci. 2014; 5(10):920-42. PMC: 4324418. DOI: 10.1021/cn500128b. View

3.
Wood M, Noetzel M, Poslusney M, Melancon B, Tarr J, Lamsal A . Challenges in the development of an M PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs. Bioorg Med Chem Lett. 2016; 27(2):171-175. PMC: 5340297. DOI: 10.1016/j.bmcl.2016.11.086. View

4.
Conn P, Lindsley C, Meiler J, Niswender C . Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov. 2014; 13(9):692-708. PMC: 4208620. DOI: 10.1038/nrd4308. View

5.
Le U, Melancon B, Bridges T, Vinson P, Utley T, Lamsal A . Discovery of a selective M₄ positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia. Bioorg Med Chem Lett. 2012; 23(1):346-50. PMC: 3535830. DOI: 10.1016/j.bmcl.2012.10.073. View